Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.
暂无分享,去创建一个
T. Golub | M. Meyerson | S. Monti | A. Lowell | D. Tenen | S. Kobayashi | B. Halmos | G. Shapiro | T. Shimamura | U. Steidl | Susumu S. Kobayashi | C. Hetherington | April M. Lowell
[1] Jill P. Mesirov,et al. Comparative gene marker selection suite , 2006, Bioinform..
[2] P. Jänne,et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. , 2006, Cancer cell.
[3] H. Varmus,et al. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. , 2006, Genes & development.
[4] M. Meyerson,et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[5] J. Mesirov,et al. GenePattern 2.0 , 2006, Nature Genetics.
[6] G. Shapiro,et al. Cyclin-dependent kinase pathways as targets for cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Fukuoka,et al. EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. , 2006, Lung cancer.
[8] J. Minna,et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.
[9] M. Ostland,et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Meyerson,et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. , 2005, Cancer research.
[11] William Pao,et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[12] A. Lowell,et al. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. , 2005, Cancer research.
[13] H. Lane,et al. ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.
[14] Patricia L. Harris,et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[15] T. Chou,et al. Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.
[16] Takayuki Kosaka,et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[18] H. Varmus,et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.
[19] Michael Peyton,et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. , 2005, Cancer research.
[20] H. Varmus,et al. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.
[21] D. Wong,et al. Cyclin G2 Dysregulation in Human Oral Cancer , 2004, Cancer Research.
[22] R. Perez-soler,et al. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. , 2004, Clinical lung cancer.
[23] J. Turkson,et al. STAT proteins as novel targets for cancer drug discovery , 2004, Expert opinion on therapeutic targets.
[24] Jean YH Yang,et al. Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.
[25] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[26] Daniel A. Haber,et al. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.
[27] Ming-Ming Zhou,et al. Structure and regulation of MAPK phosphatases. , 2004, Cellular signalling.
[28] G. Shapiro. Preclinical and Clinical Development of the Cyclin-Dependent Kinase Inhibitor Flavopiridol , 2004, Clinical Cancer Research.
[29] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[30] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[31] William Pao,et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] A. Carrera,et al. Control of Cyclin G2 mRNA Expression by Forkhead Transcription Factors: Novel Mechanism for Cell Cycle Control by Phosphoinositide 3-Kinase and Forkhead , 2004, Molecular and Cellular Biology.
[33] David Cella,et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.
[34] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Daniel L. Hartl,et al. GeneMerge - Post-genomic Analysis, Data Mining, and Hypothesis Testing , 2003, Bioinform..
[36] D. Stacey. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. , 2003, Current opinion in cell biology.
[37] Rafael A Irizarry,et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.
[38] M. Meyerson,et al. Missense mutations of the BRAF gene in human lung adenocarcinoma. , 2002, Cancer research.
[39] R. Takahashi,et al. Calpain-mediated X-linked Inhibitor of Apoptosis Degradation in Neutrophil Apoptosis and Its Impairment in Chronic Neutrophilic Leukemia* , 2002, The Journal of Biological Chemistry.
[40] R. Eckert,et al. Retinoids Suppress Epidermal Growth Factor-associated Cell Proliferation by Inhibiting Epidermal Growth Factor Receptor-dependent ERK1/2 Activation* , 2002, The Journal of Biological Chemistry.
[41] Cheng Li,et al. Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application , 2001, Genome Biology.
[42] R. Spang,et al. Role for E2F in Control of Both DNA Replication and Mitotic Functions as Revealed from DNA Microarray Analysis , 2001, Molecular and Cellular Biology.
[43] Y. Geng,et al. Specific protection against breast cancers by cyclin D1 ablation , 2001, Nature.
[44] G. Fontanini,et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[45] Y. Wan,et al. EGF receptor crosstalks with cytokine receptors leading to the activation of c-Jun kinase in response to UV irradiation in human keratinocytes. , 2001, Cellular signalling.
[46] B. Rollins,et al. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[47] M. Symons,et al. The Transcription Factor AP-1 Is Required for EGF-induced Activation of Rho-like GTPases, Cytoskeletal Rearrangements, Motility, and In Vitro Invasion of A431 Cells , 1998, The Journal of cell biology.
[48] J. Bartek,et al. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint , 1996, Molecular and cellular biology.
[49] D. Nathans,et al. In vitro activation of Stat3 by epidermal growth factor receptor kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[50] G. Qiao,et al. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2008 .
[51] P. Jänne,et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. , 2005, Journal of the National Cancer Institute.
[52] 小林 進. Calpain-mediated X-linked inhibitor of apoptosis degradation in neutrophil apoptosis and its impairment in chronic neutrophilic leukemia , 2003 .
[53] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .